2024-09-052024-09-052022-01-011124-0490https://doi.org/10.36141/svdld.v39i4.11344https://hdl.handle.net/11452/44338Background: Combined pulmonary fibrosis and emphysema (CPFE) has been recognised as a phe-notype of pulmonary fibrosis. We aimed to compare serum surfactant protein-A (SP-A), surfactant protein-D (SP-D) and Krebs von den Lungen-6 (KL-6) levels, functional parameters, in CPFE and IPF (idiopathic pul-monary fibrosis) patients. Methods: Patients diagnosed with ???CPFE??? and ???IPF??? were consecutively included in 6 months as two groups. The patients with connective tissue diseases are excluded. Results: In this study, 47 patients (41 males, 6 females) with CPFE (n = 21) and IPF (n = 26) with a mean age of 70.12 ?? 8.75 were evaluated. CPFE patients were older, had more intense smoking history, had lower DLCO/VA, lower FVC, and worse six-minute walking distance than the IPF group (p=0.005, p=0.027, p=0.02, p<0.001, p=0.001, respec-tively). Serum KL-6 levels were higher in CPFE group compared to IPF group [264.70 U/ml (228.90-786) vs 233.60 (101.8-425.4), p<0.001]. Serum KL-6 levels of 245.4 U/ml and higher have 81% sensitivity and 73% specificity for the discrimination of CPFE from IPF. Conclusions: Our study has shown that serum KL-6 level is a promising biomarker to differentiate CPFE from IPF. In CPFE cases respiratory and functional parameters are worse than those of pure fibrosis cases.eninfo:eu-repo/semantics/openAccessIdiopathic pulmonary-fibrosisSurfactant protein-aQuality-of-lifeCirculating kl-6EmphysemaHypertensionMarkersCombined pulmonary fibrosis emphysemaIdiopathic pulmonary fibrosisKrebs von den lungen-6Surfactant protein-aSurfactant protein-dPulmonary function testsEchocardiographyScience & technologyLife sciences & biomedicineRespiratory systemArticle00091148300000239410.36141/svdld.v39i4.11344